Incomplete psychoactive medication consents for multiple residents
Summary
The facility failed to identify targeted behaviors, medication classifications, and the duration of therapy on psychoactive medication informed consent forms for three residents who were receiving psychotropic medications. Resident #5 was an elderly resident with diagnoses including debility, heart failure, diabetes, anxiety, depression, bipolar disorder, and PTSD, and was receiving aripiprazole for mood stabilization and escitalopram for depression. The consent form signed by the resident did not identify which medication was for depression or mood stabilization, did not list clinically significant side effects associated with the medication classifications, left the expected benefits section blank, and did not identify targeted behaviors, even though the behavior monitoring task documented repeated movement and grabbing. Resident #6 was an elderly resident with diagnoses including a progressive neurological condition, CAD, HTN, PVD, diabetes, CVA, seizure disorder, anxiety, depression, and psychotic disorder, and was receiving risperidone and mirtazapine via PEG tube for depression, with social work documentation also noting appetite. The psychoactive medication informed consent listed duloxetine, risperidone, and mirtazapine, but the form did not identify targeted behaviors, did not identify clinically significant side effects associated with the medication classifications, and left the expected benefits section blank. The resident’s behavior monitoring task documented repeated movement, pushing, and grabbing. Resident #22 was an elderly resident with diagnoses including non-traumatic brain dysfunction, cancer, anemia, atrial fibrillation, CAD, HTN, non-Alzheimer’s dementia, anxiety, and depression, and was receiving olanzapine, trazodone, venlafaxine, buspirone, and clonazepam for psychiatric symptoms. The consent form listed mirtazapine, olanzapine, clonazepam, and trazodone, but did not identify which medication was for depression or mood stabilization, did not identify clinically significant side effects, left expected benefits blank, and did not identify targeted behaviors. The behavior monitoring task documented frequent crying, yelling and swearing, and rejection of care. The facility policy stated that prior to initiating or increasing a psychotropic medication, the resident, family, and/or representative must be informed of the benefits, risks, and alternatives, including black box warnings for antipsychotic medications, in advance of initiation or increase.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.